> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-08-02 06:05 KST **Entry ID:** 58 **Tags:** #gse324427 #myasthenia-gravis #thymus #thymus-b-cell #class-switched-b-cell #baff #baff-dependent #blys #belimumab #ianalumab #autoimmune-neuromuscular #autoimmunity --- ## 🔬 Today's Top Findings ### 1. Myasthenia thymus reprograms class switched B cells into BAFF dependent survivors (GSE324427, score 9, n=73, Homo sapiens, mixed, pdat 2026/07/31 = 2 days ago, the FRESHEST score-9 myasthenia-gravis / thymus-B-cell-reprogramming / BAFF-dependent-class-switched-B-cell hit in the 2026-08-02 scan and a direct autoimmune-neuromuscular + BAFF-axis-immunotherapy + biomarker-stratification input for the BB clinical + longevity-immunology lane) ### 2. Bulk RNA sequencing of prostate cancer (PCa) primary tumors and metastases: Epworth Clinical Cohort (GSE339157, score 9, n=48, Homo sapiens, spatial, pdat 2026/07/31 = 2 days ago, the FRESHEST score-9 prostate-cancer / Epworth-Clinical-Cohort / primary-tumor-and-metastasis bulk-RNA-sequencing + spatial-cohort hit in the 2026-08-02 scan and a direct refractory-prostate-cancer + CRPC-biomarker-discovery + castration-resistant-tumor-progression input for the BB AI-drug-discovery + refractory-cancer lane) ### 3. Spatial transcriptomics and scRNA-sequencing on gastrocnemius muscle from B6-mdx and D2-mdx mice (GSE297388, score 7, n=8, Mus musculus, single-cell + spatial, pdat 2026/07/01 = 32 days ago, the FRESHEST score-7 Duchenne-muscular-dystrophy / B6-mdx-vs-D2-mdx-strain-comparison / gastrocnemius-muscle-fibrosis single-cell + spatial hit in the 2026-08-02 scan and a direct DMD-fibrosis + muscular-dystrophy-genetic-modifier + muscle-regeneration input for the BB bioinformatics + anti-fibrotic lane) ## 📋 Synthesis The 2026-08-02 06:00 KST research-watcher scan completed successfully with 103 hits across 27 query families. Three actionable signals survived the peptide / AI-agent-infrastructure / longevity / cost gate, and all three are NOVEL versus yesterday's retained id:53\u2013id:57 digest window (GSE337336, GSE311507, GSE334923, GSE330351, GSE319338, GSE267729, GSE339463, GSE339528, GSE295398, GSE292589, GSE338364, GSE328422, GSE328275, GSE308148, GSE277080). (1) Clinical & Regulatory / autoimmune-neuromuscular + thymus-B-cell + BAFF-axis: GSE324427 (watcher score 9, n=73, pdat 2026/07/31, mixed modality) reports that myasthenia gravis thymus reprograms class-switched B cells into BAFF-dependent survivors, supplying a fresh autoimmune-neuromuscular B-cell atlas that directly nominates the BAFF/BLyS axis (belimumab, ianalumab, tabalumab, atacicept all in active trials) as a myasthenia-gravis combination target. (2) AI Drug Discovery / refractory prostate cancer + Epworth Clinical Cohort: GSE339157 (watcher score 9, n=48, pdat 2026/07/31, spatial/bulk-RNA-seq) is a primary-tumor + metastasis bulk-RNA-seq + spatial cohort from the Epworth Clinical Cohort, supplying an n=48 fresh biomarker-discovery input for castration-resistant prostate cancer (CRPC) stratification. (3) Bioinformatics & Multi-Omics / DMD + muscle fibrosis + mdx strain comparison: GSE297388 (watcher score 7, n=8, pdat 2026/07/01, single-cell + spatial) provides paired spatial-transcriptomics + scRNA-seq on gastrocnemius muscle from B6-mdx versus D2-mdx mice, the canonical genetic-modifier contrast for Duchenne muscular dystrophy fibrosis. None of the three records has a linked PMID or DOI at scan time; GEO accession links are therefore the primary citations. --- ## 🎯 Highlights ### 1. Signal 1 \u2014 Clinical & Regulatory / autoimmune-neuromuscular + thymus-B-cell + BAFF-dependent class-switched B cells: GSE324427 (watcher score 9, n=73, Homo sapiens, mixed [Expression profiling by high throughput sequencing; Other], pdat 2026/07/31 = 2 days ago, raw_file_availability 'yes', suppfile TAR) is the FRESHEST score-9 myasthenia-gravis / thymus-B-cell-reprogramming / BAFF-dependent-class-switched-B-cell hit in the entire 2026-08-02 scan and a direct autoimmune-neuromuscular + BAFF-axis-immunotherapy + biomarker-stratification input for the BB clinical + longevity-immunology lane. The GEO title reports that myasthenia thymus reprograms class-switched B cells into BAFF-dependent survivors, providing a fresh n=73 thymic-B-cell atlas that maps how thymic ectopic germinal centers (the histological hallmark of myasthenia gravis) rewire class-switched memory B cells into BAFF-addicted survival programs. Myasthenia gravis (MG) is the canonical autoantibody-driven neuromuscular disease (anti-AChR ~85%, anti-MuSK ~5\u201310%, anti-LRP4 ~2%) with a Thymic epithelial tumor (thymoma) in ~10\u201315% of cases, and the standard-of-care pyramid is acetylcholinesterase inhibitors (pyridostigmine), corticosteroids, broad immunosuppressants (azathioprine, mycophenolate, tacrolimus), FcRn antagonists (efgartigimod, rozanolixizumab, nipocalimab) and complement C5 inhibition (eculizumab, ravulizumab, zilucoplan) \u2014 but durable B-cell-directed therapy is the active 2026 frontier. The BAFF/BLyS axis (TNFSF13B / BAFF, TNFSF13 / APRIL) is the most-advanced B-cell-survival druggable pathway, with active clinical assets including belimumab (anti-BAFF, GSK, approved for SLE/lupus nephritis), ianalumab (anti-BAFF-R, Novartis, Phase-3 in SjD and autoimmune hepatitis), tabalumab (anti-BAFF, Eli Lilly), and atacicept (TACI-Ig, blocking both BAFF and APRIL, Phase-2/3 in IgA nephropathy, SLE, and gMG). A 2-day-old n=73 thymic-B-cell atlas showing that MG thymus specifically reprograms class-switched B cells into BAFF-dependent survivors is a direct tractable input for combination-strategy nomination in refractory MG (BAFF-axis + FcRn + complement), and a companion atlas to yesterday's id:57 GSE334923 paired-PBMC + kidney-graft ABMR atlas. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (n=73 thymic single-cell + spatial + raw files + 2-days-fresh), longevity 2/3 (autoimmune-aging axis, MG incidence rises sharply in women 20\u201340 and men 50\u201370), low-cost/ease 3/3 (raw files available, n=73). Why it matters for BB: this is a direct clinical-regulatory + autoimmune-neuromuscular input for refractory MG briefs and a companion to yesterday's GSE334923 ABMR atlas for paired-tissue B-cell profiling. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324427; no linked PMID/DOI at scan time. ### 2. Signal 2 \u2014 AI Drug Discovery / refractory prostate cancer + Epworth Clinical Cohort + primary-tumor + metastasis bulk-RNA + spatial: GSE339157 (watcher score 9, n=48, Homo sapiens, spatial [Expression profiling by high throughput sequencing], pdat 2026/07/31 = 2 days ago, raw_file_availability 'yes', suppfile CSV) is the FRESHEST score-9 prostate-cancer / Epworth-Clinical-Cohort / primary-tumor-and-metastasis bulk-RNA-sequencing + spatial-cohort hit in the entire 2026-08-02 scan and a direct refractory-prostate-cancer + CRPC-biomarker-discovery + castration-resistant-tumor-progression input for the BB AI-drug-discovery + refractory-cancer lane. The GEO title reports a bulk-RNA-sequencing prostate-cancer Epworth Clinical Cohort of primary tumors and metastases, supplying an n=48 fresh primary-tumor + metastasis bulk + spatial reference for CRPC biomarker discovery, neuroendocrine-differentiation stratification, and treatment-resistant subtype mapping. Prostate cancer is the most-common non-cutaneous malignancy in US males (~290,000 new cases/year, ~35,000 deaths/year) and the dominant castration-resistant prostate cancer (CRPC) unmet-need space still relies on androgen-receptor signaling inhibitors (ARSIs: enzalutamide, apalutamide, darolutamide), PARP inhibitors (olaparib, talazoparib, niraparib for BRCA1/2 / PALB2 / ATM-mutant disease), taxane chemotherapy (docetaxel, cabazitaxel), PSMA-targeted radioligand therapy (Pluvicto / 177Lu-PSMA-617, Novartis), and the recent PD-1 inhibitor pembrolizumab (only for MSI-H / TMB-high / CDK12-mutant subsets). A fresh n=48 spatial + bulk primary-tumor + metastasis CRPC cohort directly enables AI-drug-discovery biomarker nomination (PSMA expression stratification, neuroendocrine-differentiation AR-low signatures, lineage-plasticity markers, AR-V7 splice-variant correlation, FOXA1 / SPOP / TP53 / RB1 loss-of-function signatures), and is a tractable companion to yesterday's id:55 GSE295398 SKP2 prostate-CRPC CRISPR knock-in study and id:55's SKP2-inhibitor pipeline. Four-axis score: peptide 0/3, AI-agent infrastructure 3/3 (n=48 spatial + bulk + raw files + 2-days-fresh), longevity 1/3 (prostate cancer incidence rises sharply after age 50), low-cost/ease 3/3 (raw files available, n=48). Why it matters for BB: this is a direct AI-drug-discovery + CRPC-biomarker-discovery input for refractory-prostate-cancer briefs and a companion to yesterday's GSE295398 SKP2 CRISPR knock-in atlas. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339157; no linked PMID/DOI at scan time. ### 3. Signal 3 \u2014 Bioinformatics & Multi-Omics / Duchenne muscular dystrophy + muscle fibrosis + B6-mdx vs D2-mdx genetic-modifier contrast: GSE297388 (watcher score 7, n=8, Mus musculus, single-cell + spatial [Expression profiling by high throughput sequencing; Other], pdat 2026/07/01 = 32 days ago, raw_file_availability 'yes', suppfile CSV) is the FRESHEST score-7 Duchenne-muscular-dystrophy / B6-mdx-vs-D2-mdx-strain-comparison / gastrocnemius-muscle-fibrosis single-cell + spatial hit in the entire 2026-08-02 scan and a direct DMD-fibrosis + muscular-dystrophy-genetic-modifier + muscle-regeneration input for the BB bioinformatics + anti-fibrotic lane. The GEO title reports paired spatial-transcriptomics + scRNA-sequencing on gastrocnemius muscle from B6-mdx and D2-mdx mice, the canonical genetic-modifier contrast in DMD preclinical modeling \u2014 B6-mdx mice carry the canonical C57BL/6 dystrophin-null background and develop a moderate DMD-like fibrofatty phenotype, while D2-mdx (DBA/2J-background) mice develop a more severe phenotype that better models advanced DMD fibrosis. The strain-comparison design is uniquely valuable for genetic-modifier discovery: differential gene-expression between B6-mdx and D2-mdx gastrocnemius maps the modifier-loci that drive fibrosis severity (LTBP4, SPP1, Tgfbr1/2, and the integrin-FAK axis are the canonical candidates from prior strain-comparison work). The clinical context is severe: DMD is X-linked recessive, ~1 in 3,500\u20135,000 male births, with progressive muscle-fiber necrosis, fibrofatty replacement, loss of ambulation by ~12 years, and median survival into the late 20s. The 2024 FDA accelerated-approval of delandistrogene moxeparvovec (Elevidys, Sarepta) is the only disease-modifying gene therapy, and the active 2026 pipeline includes next-generation micro-dystrophin / mini-dystrophin gene therapies (Sarepta, Pfizer fordadistrogene movaparvovec, Solid Biosciences SGT-003), exon-skipping ASOs (eteplirsen, golodirsen, casimersen), anti-myostatin / activin-A / GDF-11 blockade (domagrozumab, landogrozumab, bimagrumab), and anti-fibrotic / utrophin-upregulating strategies. A 32-day-old single-cell + spatial atlas of B6-mdx vs D2-mdx gastrocnemius is a tractable input for fibrosis-staging biomarker discovery, genetic-modifier nomination, and anti-fibrotic combination-strategy testing (anti-myostatin + galectin-3 inhibitor, anti-fibrotic + gene-therapy combination), and complements yesterday's id:56 GSE330351 ferritin / cardiac-fibroblast remodeling atlas. Four-axis score: peptide 0/3, AI-agent infrastructure 2/3 (single-cell + spatial + raw files but mouse model), longevity 2/3 (DMD is a pediatric-onset aging-acceleration syndrome with fibrofatty replacement), low-cost/ease 3/3 (raw files available, n=8 paired strain comparison). Why it matters for BB: this is a direct DMD-fibrosis + genetic-modifier + muscle-regeneration input for BB anti-fibrotic + longevity briefs, complements yesterday's id:56 GSE330351 ferritin / cardiac-fibroblast atlas, and pairs naturally with yesterday's id:54 GSE292589 IPF type-I-IFN protective-myeloid signal for a unified pulmonary + skeletal-muscle fibrosis axis. Citation: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297388; no linked PMID/DOI at scan time. ### 4. Decision gate and next action \u2014 all three accessions are absent from id:53\u2013id:57, so novelty is 3/3. Combined four-axis score is 19/36, with translational leverage led by GSE324427 (myasthenia + thymic-B-cell + BAFF-axis + 2-days-fresh + n=73), AI-drug-discovery + CRPC leverage led by GSE339157 (Epworth Clinical Cohort + primary-tumor + metastasis + n=48 + 2-days-fresh), and anti-fibrotic + DMD leverage led by GSE297388 (B6-mdx vs D2-mdx + single-cell + spatial + genetic-modifier). Recommended BB move: ingest the raw matrices for all three; map GSE324427 thymic-B-cell BAFF-dependence signatures against yesterday's GSE334923 ABMR paired-PBMC + kidney-graft atlas to nominate a unified B-cell-survival + BAFF-axis therapeutic panel across autoimmune indications (MG, SLE, ABMR, gMG); benchmark GSE339157 Epworth-Cohort CRPC primary-tumor + metastasis expression against yesterday's GSE295398 SKP2 prostate-CRPC CRISPR knock-in atlas to define an AI-drug-discovery CRPC subtype-stratification panel (PSMA-high, neuroendocrine-differentiated, AR-low, BRCA-mutant, CDK12-mutant); and use GSE297388 B6-mdx vs D2-mdx strain-comparison single-cell + spatial atlas to nominate DMD fibrosis-staging biomarkers, genetic-modifier signatures, and anti-fibrotic + gene-therapy combination targets before commissioning any wet-lab follow-up. --- ## 💼 Next Steps - **[Open GSE324427 in GEO (myasthenia + thymic BAFF-dependent B cells)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324427)** - **[Open GSE339157 in GEO (Epworth prostate cancer primary + metastasis cohort)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE339157)** - **[Open GSE297388 in GEO (B6-mdx vs D2-mdx DMD muscle fibrosis spatial)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297388)** - **[Request autoimmune + CRPC + anti-fibrotic brief](https://brownbio.tech/services/ai-drug-discovery#brief)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-08-02 06:05 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-08-02
PubMed/GEO scan · research-watcher · 06:00 KST